Renal Cell Carcinoma Diagnostics
Advertisement
Drs. Joyce and Jani look toward the future of liquid biopsy in RCC care and how new technology, like AI, will play a role.
Drs. Joyce and Jani discuss practical clinical cases of using liquid biopsy to manage patients in different RCC settings.
Drs. Joyce and Jani talk about the technique of liquid biopsy and its role as a diagnostic tool in RCC.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.